Opendata, web and dolomites

OVOMATIC

IN-OVO AUTOMATION FOR CANCER DRUG DISCOVERY

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 OVOMATIC project word cloud

Explore the words cloud of the OVOMATIC project. It provides you a very rough idea of what is the project "OVOMATIC" about.

perform    2009    eliminate    viallet    mainly    molecules    anti    months    fewer    africa    2014    proprietary    dedicate    cover    precede    insufficient    ovo    currently    commercial    societal    spin    automating    solving    diseases    uk    issue    save    reproducible    pathologies    molecule    chick    czech    play    big    euros       toxicity    drugs    successful    efforts    sensitive    head    confirmed    productivity    revolutionize    model    severe    mouse    arab    market    introduce    150    stage    robot    france    cancer    share    pharmaceutical    assays    japan    240    financial    tested    discovery    finalise    drug    automatable    prototype    small    treatments    meet    consuming    obstacle    industry    emirates    embryos    initiate    ovomatic    south    off    time    biotechs    worldwide    university    40k    clients    inovotion    landscape    expensive    vivo    founded    tests    tool    grenoble    performed    republic    demand    orphan    automated    always    efficacy    academics    strategies    usa    billion    pharma    evaluation    united    huge    fast    prof   

Project "OVOMATIC" data sheet

The following table provides information about the project.

Coordinator
INOVOTION 

Organization address
address: BIOPOLIS 5 AVE DU GRAND SABLON
city: LA TRONCHE
postcode: 38700
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://www.inovotion.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-01-01   to  2017-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INOVOTION FR (LA TRONCHE) coordinator 50˙000.00

Map

 Project objective

Currently, the in vivo step in the drug discovery process is always performed using the mouse model. This step is expensive and time-consuming, with an average cost of 40k€ per molecule tested and an average duration of 6-9 months. It represents a huge obstacle for the pharmaceutical industry, leading to fewer new drugs brought to market each year, and insufficient treatments for severe pathologies such as cancer or orphan diseases. INOVOTION can play a major role in solving this huge societal issue: we have the technology to revolutionize drug discovery by automating in vivo drug evaluation for efficacy and toxicity. INOVOTION is a spin-off of the University of Grenoble, founded in 2014 by Prof. Viallet. Our researchers have been working since 2009 on a new proprietary technology to perform “in ovo” assays that precede mouse testing, using chick embryos. Our tests allow researchers to eliminate low-value molecules at an early stage in the process, and to dedicate mouse testing for high-potential molecules only. Furthermore, our technology is reliable, reproducible, highly sensitive, fast and automatable. The successful 150 studies we performed for big pharma, small biotechs and academics (in the USA, France, UK, Japan, South Africa, Czech Republic and the United Arab Emirates) have confirmed the market demand for our technology. The worldwide market for in vivo testing is about 30 billion euros per year, mainly for cancer research, and INOVOTION has the technology to meet the market's needs. For each 1% in market share we cover, we could save the pharmaceutical industry up to 240 M€. The OVOMATIC project aims to initiate an automated “in ovo” process including developing a robot tool head prototype, and finalise the commercial and financial strategies of our approach. The long-range impact of the OVOMATIC project is to introduce this new tool into the pharmaceutical landscape, greatly increasing the productivity of our clients' anti-cancer drug discovery efforts.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OVOMATIC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OVOMATIC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.4.;H2020-EU.2.3.1.)

FlexiBiome (2018)

Next Generation Microbiome Platform

Read More  

SEQURE (2018)

Targeted complete next-generation sequencing for companion diagnostics and personalized treatment of cancer

Read More  

sFilm-FS (2018)

Fibrin sealant for anastomotic leaks and haemostasis

Read More